Marijo Bilusic

17PUBLICATIONS
66CO-AUTHORS
Predictive and prognostic markersMolecular targetsRadiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 14, 2026
Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.

|Apr 06, 2026
The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients.

Marijo Bilusic, Durga Prasad Gannamedi, Bhipasha Challu

|Oct 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching

|Mar 03, 2025
Overcoming common emerging barriers to effective neoadjuvant immunotherapies.

Sophia Sokol, Marijo Bilusic

|Oct 10, 2024
Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.

Ling Zhang, Clara I Troccoli, Beatriz Mateo-Victoriano

|Jan 14, 2023
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.

Margaret E Gatti-Mays, Nicholas P Tschernia, Julius Strauss

Pageof 3

Frequent Collaborators

11 joint publications

James L Gulley

9 joint publications

Ravi A Madan

6 joint publications

Jeffrey Schlom

6 joint publications

Fatima Karzai